Accumulating evidence indicates that cyclooxygenase (COX)-2-derived prostaglandin (PG) E 2 is involved in the development of various tumors, including colorectal cancer. However, the precise contribution of microsomal PGE synthase (mPGES)-1, a terminal enzyme that acts downstream of COX-2 in the PGE 2 -biosynthetic pathway, to multiple processes of tumor development is not yet fully understood. Here, we show the pro-tumorigenic role of mPGES-1 in chemical carcinogen-induced colon carcinogenesis and intrasplenic tumor transplantation models. Genetic deletion of mPGES-1 significantly reduced both the total number and size of colorectal polyps at 18 weeks after azoxymethane administration with reduced nuclear translocation of b-catenin, altered expression profiles of chemokines/cytokines and increased production of antitumorigenic PGs, prostaglandin D 2 and prostacyclin in tumor tissues. At an early stage (6 weeks), mPGES-1 deficiency significantly reduced the number of aberrant crypt foci, while its transgenic overexpression increased the number. Furthermore, the growth of intrasplenically transplanted tumor cells was suppressed in mPGES-1 knockout (KO) mice. Co-culture of tumor cells with bone marrow-derived macrophages (BM-MUs) isolated from wild-type (WT) mice resulted in the induction of mPGES-1 in BM-MUs and increased the growth of tumor cells in vitro, whereas mPGES-1-null BM-MUs failed to facilitate tumor growth. The adoptive transfer of WT BM-MUs into mPGES-1 KO mice restored the growth of transplanted tumor cells, indicating that mPGES-1 in MUs is important for the growth of adjacent tumor cells. Taken together, our findings suggest that the inhibition of mPGES-1 is an alternative therapeutic target for colorectal and possibly other cancers.
Introduction
Colorectal cancer (CRC) is one of the most common neoplasias in western countries and the second leading cause of cancer-related death (Jemal et al., 2010) . A large body of evidence indicates that the use of aspirin and other non-steroidal anti-inflammatory drugs can reduce the risk of CRC (Wang and DuBois, 2010a) . Experimental studies have demonstrated that these drugs decrease the incidence of carcinogen-induced colon tumors in rodents, and several epidemiological investigations and therapeutic trials have also shown a 40-50% reduction in the risk of colorectal adenoma and cancer in individuals taking non-steroidal antiinflammatory drugs. A well-known effect of nonsteroidal anti-inflammatory drugs is their ability to inhibit the enzyme cyclooxygenase (COX) and thereby to suppress prostaglandin (PG) synthesis. Of the two COX isoforms, COX-1 is expressed constitutively in most tissues and is generally responsible for the production of PGs that control normal physiological functions, while COX-2 is inducible in response to mitogens, cytokines and cellular transformation. High levels of constitutive expression of COX-2 and its major product, PGE 2 , have been detected in various tumors, including CRC (Wang and DuBois, 2010a) . PGE 2 is involved in tumor progression by inducing angiogenesis, invasion and metastasis in several solid tumors (Wang and DuBois, 2010b) . Moreover, pharmacological, cell biological and gene targeting studies investigating COX-2 have demonstrated that PGE 2 produced through the COX-2-dependent pathway contributes to the progression of several types of cancer (Tsujii and DuBois, 1995; Tsujii et al., 1998) . Although the inhibition of COX-2-mediated PGE 2 formation represents a promising chemopreventive strategy for reducing the risk of cancer, the cardiovascular side effects associated with COX-2 inhibitors, which most likely result from the blunting of anti-thrombotic prostacyclin (PGI 2 ), have recently been found to limit their use (Bombardier et al., 2000; Bresalier et al., 2005) . From this viewpoint, selective blockage of the biosynthesis of PGE 2 without affecting other prostanoids appears to be feasible for cancer chemoprevention with the potential for improved tolerability over non-steroidal anti-inflammatory drugs.
Prostaglandin H 2 produced by COX is converted to PGE 2 by PGE synthase (PGES). Thus far, three PGES enzymes have been identified: microsomal PGES (mPGES)-1, mPGES-2 and cytosolic PGES (Murakami and Kudo, 2004; Nakatani, 2007; Hara et al., 2010) . Among these PGES enzymes, mPGES-1 is induced by proinflammatory stimuli and downregulated by antiinflammatory glucocorticoids, as in the case of COX-2, and is functionally coupled with COX-2 in marked preference to COX-1 (Jakobsson et al., 1999; Murakami et al., 2000; Mancini et al., 2001; Stichtenoth et al., 2001) . Induction of mPGES-1 expression and its function have been observed in various diseases and systems in which COX-2-driven PGE 2 has been implicated, such as rheumatoid arthritis, febrile response, reproduction, bone metabolism, cardiovascular function, stroke and Alzheimer's disease (Kamei et al., 2004; Samuelsson et al., 2007; Hara et al., 2010) . It has also been reported that mPGES-1 is constitutively expressed in several cancers, most of which also express COX-2 constitutively (Kamei et al., 2003; Golijanin et al., 2004) . We have reported that the forcible transfection of mPGES-1 in combination with COX-2, but not with COX-1, into HEK293 cells led to cellular transformation, with a concomitant and robust increase in PGE 2 (Kamei et al., 2003) . Transgenic mice overexpressing both COX-2 and mPGES-1 developed metaplasia, hyperplasia and tumorous growth in the glandular stomach with heavy macrophage (MF) infiltration (Oshima et al., 2004 (Oshima et al., , 2005 . Furthermore, cell proliferation and invasive activity in vitro and xenograft formation in vivo were reduced by mPGES-1 knockdown and conversely enhanced by mPGES-1 overexpression in lung and prostate cancer cells (Hanaka et al., 2009; Kamei et al., 2010) . To better evaluate the efficacy of mPGES-1 inhibition in relieving symptoms of cancer, we herein examined the effect of mPGES-1 deficiency on chemical carcinogen-induced carcinogenesis and found that the absence of mPGES-1 reduces the size and number of colorectal polyps. Furthermore, we found that the induction of mPGES-1 in MFs within a tumor microenvironment was important for the growth of intrasplenically transplanted tumor cells. Our findings suggest that the inhibition of mPGES-1 is an alternative therapeutic target for cancer, including CRC.
Results
Suppression of azoxymethane-induced colon carcinogenesis in mPGES-1 KO mice To investigate in vivo the tumorigenic potential of mPGES-1, we first bred the mPGES-1-null allele onto Balb/c mice, a mouse strain that is sensitive to azoxymethane (AOM)-induced colon carcinogenesis (Nambiar et al., 2003) . Then, mPGES-1 knockout (KO) and littermate wild-type (WT) mice on the Balb/ c background were intraperitoneally injected with AOM once a week over the initial 6 weeks and were killed at 18 weeks after the last injection. We found that AOM administration induced the development of multiple tumors in the middle to distal colon of WT mice, while the induction of tumors was dramatically suppressed in mPGES-1 KO mice ( Figure 1a ). As shown in Figure 1b , mPGES-1 deficiency reduced the total number of polyps in the colon after AOM treatment, and large (>2 mm) polyps were markedly reduced in the mPGES-1-deficient colon. Histologically, adenocarcinomas in the mPGES-1 KO mice were considerably smaller than those in WT mice (Figure 1c) .
Furthermore, our immunohistochemical analysis revealed that mPGES-1 was induced in adenocarcinomas in the WT mice, while no immunostaining signal for mPGES-1 was observed in the AOM-treated colon in mPGES-1 KO mice (Figure 2a ). mPGES-1 was expressed in the cancer cells as well as in leukocytes invading into the stroma of the carcinoma region in the WT mice ( Figure 2b ). We next analyzed the expression levels of enzymes involved in PGE 2 synthesis by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). As shown in Figure 2c , both mPGES-1 and COX-2 mRNA levels in tumor tissues were substantially higher than those in normal areas of the colon in the same mouse. The elevated expression of COX-2 occurred similarly in mPGES-1 KO and WT mice. The mPGES-1 deficiency did not affect the expression levels of other enzymes involved in the biosynthesis and catabolism of PGE 2 , including cytosolic phospholipase A 2 a (an enzyme that supplies arachidonic acid to COX-2), cytosolic PGES and mPGES-2 (the other two PGES enzymes) and 15-hydroxyprostaglandin dehydrogenase (an enzyme that inactivates PGE 2 ) (data not shown). We next examined the effect of mPGES-1 deficiency on PG levels in the colon. In the colon of AOM-treated WT mice, the PGE 2 level in tumor tissues tended to be higher than that in normal tissues (Figure 2d ). Its level in normal tissues from AOM-treated mice was comparable with that from non-treated mice (data not shown). As expected, PGE 2 levels in both normal and tumor tissues of mPGES-1 KO mice were markedly lower (even though substantially present) than those in WT mice, confirming that mPGES-1 deficiency suppressed AOM-induced colon carcinogenesis by reducing PGE 2 levels in the colon. We further found that the levels of prostaglandin D 2 (PGD 2 ) and 6-ketoPGF 1a (a stable metabolite of PGI 2 ), but not that of PGF 2a , in the tumor tissues of mPGES-1 KO mice were significantly higher than those in WT mice (Figure 2d ). The level of thromboxane B 2 (a stable metabolite of thromboxane A 2 ) also tended to be higher in mPGES-1-deficient tissues, but the difference in thromboxane B 2 level was not statistically significant. Thus, in the mPGES-1-deficient colon tissues, COX-2-derived prostaglandin H 2 is metabolically shunted into the PGD 2 /PGI 2 -synthetic pathway. In this regard, Boulet et al. (2004) have also shown that mPGES-1 deficiency increased the production of PGs other than PGE 2 in the gastric mucosa.
Effects of mPGES-1 deficiency on pro-and antitumorigenic signaling PGE 2 has been shown to play a role in the indirect activation of b-catenin via inactivation of axin and glycogen synthase 3b (Castellone et al., 2005) . Nuclear b-catenin functions as a transcription cofactor of the T-cell factor/lymphoid enhancer factor family and leads to the activation of Wnt signaling, which is associated with CRC progression (Segditsas and Tomlinson, 2006) . Therefore, we next investigated the effect of mPGES-1 deficiency on b-catenin expression and localization by immunohistochemical analysis. In AOM-treated colons of WT mice, b-catenin immunostaining signals were higher in tumor cells than that in normal colorectal epithelial cells (Figure 3a, upper panel) . In these mice, b-catenin was present in the cytoplasm of normal epithelial cells, whereas both extensive nuclear accumulation and cytoplasmic localization of b-catenin were observed in tumor cells. On the other hand, b-catenin was distributed mostly in the cytoplasm, not in the We further examined the effects of mPGES-1 deficiency on the expression levels of chemokines and cytokines in tumor tissues and found that mRNA levels of CCL5, and to a lesser extent than those of CXCL12, in mPGES-1 KO mice were significantly higher than those in WT mice ( Figure 3b ). Interleukin-1b and interferon-g levels also tended to be higher in mPGES-1-deficient colon tumor tissues. Among them, the expression level of CCL5, the chemokine with the most notable increase by the absence of mPGES-1, in tumor tissues was lower than that in normal tissues in the same WT mouse (Figure 3c ). On the other hand, mPGES-1 knockdown did not affect the CCL5 expression in Lewis lung carcinoma LLC cells, although both expressions of CCL2 and CXCL14 were reduced (Supplementary Figure 1) . Tumor-secreted PGE 2 inhibited the production of CCL5 in MFs (Qian et al., 2011) . Expression of CCL5 might be regulated by cell-cell communication via PGE 2 between cancer cells and tumor-associated MFs. It has been shown that overexpression of CCL5 in the thymoma cell lines inhibited tumor growth when injected into mice, with increased recruitment of T cells, natural killer cells and dendritic cells (Lavergne et al., 2004) . Thus, mPGES-1 deficiency may suppress AOMinduced colon carcinogenesis partly by affecting the production of the antitumor chemokine CCL5.
As described above, the production of PGD 2 and that of PGI 2 in the tumor tissues were increased by mPGES-1 deficiency (Figure 2d ). It has been known that PGD 2 and PGI 2 are anticarcinogenic agents (Keith et al., 2004; Park et al., 2007; Cathcart et al., 2010) . PGD 2 is rapidly metabolized to 15-deoxy-D 12,14 -PGJ 2 , which inhibits tumor growth via a peroxisome proliferator-activated receptor g (PPARg)-dependent or -independent pathway (Scher and Pillinger, 2005; Mansure et al., 2009). 15-Deoxy-D 12,14 -PGJ 2 acts as an endogenous PPARg ligand or as an inhibitor of several pro-inflammatory/ pro-tumorigenic signal-transduction pathways, including the nuclear factor-kB (NF-kB) pathway. As shown in Figure 3d , the mRNA level of PPARg in WT mice was reduced in tumor tissues compared with normal tissues, whereas it was elevated in tumor tissues of mPGES-1 KO mice over those of WT mice. Furthermore, the protein level of inhibitor of NF-kB (IkB) was increased in tumor tissues of mPGES-1 KO mice (Figure 3e ). These results suggest that, in tumor tissues, mPGES-1 deficiency may increase the level of the PGD 2 metabolite, 15-deoxy-D 12,14 -PGJ 2 , which may in turn suppress colon carcinogenesis by activating antitumorigenic PPARg and inhibiting pro-tumorigenic NF-kB.
Suppression of AOM-induced aberrant crypt foci formation in mPGES-1 KO mice and its enhancement in mPGES-1 transgenic mice To examine the effect of mPGES-1 deficiency on preneoplastic ACF formation in an early phase of colon 
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Y Sasaki et al carcinogenesis, we next killed animals 6 weeks after the last AOM injection. Our immunohistochemical analysis revealed that mPGES-1 was induced in an early stage of colon carcinogenesis (Figure 4a ). Furthermore, mPGES-1 deficiency significantly reduced the number of ACF, with the frequency of large-sized ACF consisting of more than four crypts showing the greatest suppression ( Figure 4b ). Next, to examine whether or not mPGES-1 overexpression would have an opposite effect, we generated transgenic mice that overproduced mPGES-1 under the control of the chicken b-actin promoter. In this experiment, we used transgenic mice on the C57BL/6 background, which has been well characterized as being highly resistant to AOM-induced colon carcinogenesis (Nambiar et al., 2003) . As shown in Figure 4c , transgenic mice had high expression of mPGES-1 and high production of PGE 2 in colon tissues. In mPGES-1 transgenic mice, spontaneous colon carcinogenesis did not occur, but after treatment with AOM, the number of large-sized ACF was significantly increased (Figure 4d ). These results from KO and transgenic mice together suggest that overproduction of mPGES-1-derived PGE 2 facilitates tumor propagation even though it is not sufficient for tumor initiation.
Reduced growth of intrasplenically transplanted tumor cells in mPGES-1 KO mice
We recently found that not only cancer cell-associated mPGES-1, but also host stromal cell-associated mPGES-1 contributes to tumor growth, invasion and metastasis . Our previous immunohistochemical analyses demonstrated a preferential localization of mPGES-1 in MF-like cells infiltrating the stromal tissues in proximity to cancer cells (Kamei et al., 2003) . As shown in Figure 2b , mPGES-1 was expressed in leukocytes invading into the stroma of the colon carcinoma region in the AOM-treated mice. Thus, we next investigated the involvement of mPGES-1 expressed in MFs surrounding cancer cells in tumor growth in vivo and in vitro. We transplanted colon carcinoma colon-26 cells or Lewis lung carcinoma LLC cells into the spleens of WT and mPGES-1 KO mice on the Balb/c or C57BL/6 background, respectively, and tumor development was evaluated. On day 28 after the transplantation of colon-26 (Figure 5a ) or LLC cells (Figure 5b ), spleen weights were reduced by half in the cells had been intrasplenically transplanted into mPGES-1 KO mice compared with WT mice. Furthermore, liver metastasis was observed in 2 of 11 mice when colon-26 cells had been intrasplenically transplanted into WT mice, whereas no metastasis was observed in replicate mPGES-1 KO mice (Figure 5c ). These results indicate that mPGES-1-derived PGE 2 produced from some spleen-resident cells may promote tumor growth and metastasis. We next prepared bone marrow-derived MFs (BM-MFs) from WT mice, and found that coculture of BM-MFs with LLC cells increased mPGES-1 expression. As shown in Figure 6a , our immunocytochemical analysis revealed that mPGES-1 was expressed in LLC cells, but not in BM-MFs when cultured alone, whereas an mPGES-1 signal was detected at the perinuclear area in MFs co-cultured with LLC cells. Furthermore, the in vitro growth of LLC cells was substantially increased by co-culture with WT-derived BM-MFs, whereas KO-derived BM-MFs did not affect their growth (Figure 6b ). These results suggest that LLC cells induced mPGES-1 expression in MFs and that mPGES-1-derived PGE 2 produced by MFs increased LLC growth. Likewise, in vitro growth of colon-26 cells was also increased by co-culture with WT, but not KO-derived BM-MFs (data not shown). To verify the in vivo relevance of these observations, we next examined whether WT-derived BM-MFs could restore the reduced growth of LLC cells in the spleens of mPGES-1 KO mice. Notably, adoptive transfer of WT-derived BM-MFs greatly facilitated tumor growth, whereas KO-derived BM-MFs failed to do so (Figure 6c ). These results indicate that the induction of mPGES-1 in MFs in a tumor microenvironment is important for tumor growth.
Discussion
The development of colon cancer is a consequence of multiple processes. In this study, we found that mPGES-1 deficiency suppresses chemical carcinogen-induced colon Figure 1 , genetic deletion of mPGES-1 significantly reduced both the total number and size of polyps in the colon after AOM administration. Nakanishi et al. (2008) also recently reported that the introduction of mPGES-1 gene deletion onto Apc D14/ þ mice, in which spontaneous intestinal and colon carcinogenesis occurred, reduced the number and size of polyps. Taken together with this previous report, this study has provided additional lines of evidence that mPGES-1-derived PGE 2 promotes multiple steps in colon carcinogenesis.
As demonstrated in a study by Nakanishi et al. (2008) , we have herein found that AOM-induced pre-neoplastic ACF formation in an early phase of colon carcinogenesis was suppressed by the lack of mPGES-1, with a reduction in the number of large ACF (Figure 4 ). In addition, we further found that the formation of large ACF was enhanced by transgenic overexpression of mPGES-1, although spontaneous colon carcinogenesis did not occur. These results suggest that overproduction of mPGES-1-derived PGE 2 is not sufficient for initiating colon carcinogenesis, but is crucially involved in ACF formation. We previously reported that the forcible transfection of mPGES-1 in combination with COX-2 into HEK293 cells led to cellular transformation with a concomitant and robust increase in PGE 2 (Kamei et al., 2003) . It was also shown that overexpression of COX-2 induced genomic instability in MCF10A breast cancer cells (Singh et al., 2007) and that AOM-induced colon tumors in mice were chromosomally stable and were characterized by low-level microsatellite instability (Guda et al., 2004) . mPGES-1-derived PGE 2 might enhance chemical carcinogen-initiated colon carcinogenesis by the induction of genomic instability.
In addition to ACF formation, several tumorigenic and antitumorigenic signaling pathways in AOMtreated colons were also affected by mPGES-1 deficiency. Castellone et al. (2005) showed that PGE 2 stimulates colon cancer growth through the EP2-Aktglycogen synthase 3b axis, leading to b-catenin nuclear translocation and accumulation. mPGES-1 deficiency blocked b-catenin activation, apparently by reducing PGE 2 levels in colon tumors (Figures 2d and 3a) . As shown in Figure 3b , among chemokines and cytokines, expression of CCL5, and to a lesser extent the expression of CXCL12, interleukin-1b and interferon-g, were upregulated by mPGES-1 deficiency. Several chemokines including CCL5 have bidirectional effects on tumor progression (Hembruff and Cheng, 2009 ). For instance, overexpression of CCL5 in the thymoma cell lines EL4 or EG7 inhibited tumor growth when injected in mice (Lavergne et al., 2004) . In contrast, when 410.4 breast cancer cells were transplanted into mice, daily systemic treatment of a functional antagonist to CCL5 
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Y Sasaki et al reduced MF infiltration into the tumor tissues and slowed tumor growth (Robinson et al., 2003) . These observations suggest that the ability of chemokines to stimulate or suppress tumor progression may be cancer type-or stage-specific. Although further studies are needed to clarify the involvement of chemokines in colon carcinogenesis, the elevated expression of interferon-g in mPGES-1-null tumor tissues might be a reflection of CCL5-mediated recruitment of interferong-producing lymphocytes (for example, CD8 þ T cells or natural killer cells), which could contribute to tumor suppression. Consistent with this speculation, during our preparation of this paper, Nakanishi et al. (2011) reported that mPGES-1 deletion suppressed AOMinduced colon carcinogenesis, where the total numbers of CD8 þ and CD4 þ cells were markedly elevated in mesenteric lymph nodes in AOM-treated mPGES-1 KO mice. Thus, mPGES-1-derived PGE 2 may modify local mucosal immunity associated with colon carcinogenesis.
mPGES-1 deficiency also resulted in the activation of the PPARg pathway and suppression of the NF-kB pathway in AOM-induced colon carcinogenesis (Figure 3) . Reportedly, PPARg agonists significantly suppress AOM-induced colon carcinogenesis (Osawa et al., 2003) and act as potent inductors of growth arrest and apoptotic cell death in cancers, including colon cancer (Thompson, 2007) . On the other hand, activation of NF-kB is associated with cell proliferation, cell cycle progression, tumor growth promotion, angiogenesis and metastasis through the expression of genes participating in malignant conversion and tumor promotion (Garg and Aggarwal, 2002) . The cell growth inhibitory effects of PPARg agonists are most likely ascribed to the decrease in NF-kB activity (Ban et al., 2010) . In colon tumor tissues derived from mPGES-1 KO mice, PGD 2 production was higher than that in WT mice through the process known as prostaglandin H 2 metabolite shunting (Figure 2d) . Park et al. (2007) reported that in Apc Min/ þ mice, overexpression of hematopoietic PGD synthase suppressed intestinal adenomas, while its deletion conversely increased them. PGD 2 is metabolized to 15-deoxy-D 12,14 -PGJ 2 , which can activate PPARg and inhibit IkB kinase (Scher and Pillinger, 2005; Mansure et al., 2009) , thereby being thought to function as an anti-carcinogenic PG. It is thus conceivable that the elevated PGD 2 may be functionally linked to the increased PPARg and the decreased NF-kB in tumor tissues of mPGES-1 KO mice. It was also shown that pulmonary PGI synthase overexpression suppressed tobacco smoke-induced lung carcinogenesis in mice (Keith et al., 2004) , indicating that PGI 2 , as well as PGD 2 , can be regarded as an anti-carcinogenic PG. As shown in Figure 2 , ablation of mPGES-1 resulted not only in the suppression of carcinogenic PGE 2 production, mPGES-1 promotes colon carcinogenesis Y Sasaki et al but also in the reciprocal upregulation of anti-carcinogenic PGD 2 /PGI 2 production. Thus, in light of the fact that inhibition of COX-2 suppresses both pro-and antitumorigenic PGs, an mPGES-1-specific inhibitor, which blunts pro-tumorigenic PGE 2 while increasing antitumorigenic PGD 2 and PGI 2 , is expected to be a more effective anticarcinogenic agent than a COX-2-specific inhibitor.
Furthermore, we found that mPGES-1 expression was increased in MFs in proximity to tumor cells, a process that was important for tumor growth (Figures 2b, 5 and 6) . Considering that tumor cells release several cytokines and growth factors that are capable of inducing mPGES-1, such as interleukin-1b, tumor necrosis factor-a and vascular endothelial growth factor (Caso´s et al., 2011) , some of these factors secreted from tumor cells may be involved in the induction of mPGES-1 in adjacent MFs. The role of cancer cell-associated mPGES-1 in tumor growth has been demonstrated in studies employing knockdown of mPGES-1 in several tumor cell lines, where its knockdown in LLC cells, the human prostate cancer cell line DU145 and the nonsmall-cell lung cancer cell line A549 reduced their growth in vitro and/or in vivo (when transplanted into mice) (Hanaka et al., 2009; Kamei et al., 2010) . We recently found that, in addition to cancer cell-associated mPGES-1, host stromal cell-associated mPGES-1 contributes to tumor growth, in which LLC tumors grafted subcutaneously into mPGES-1 KO mice grew more slowly than did those grafted into WT mice, due at least in part to reduced angiogenesis . In good agreement with this study, mPGES-1-expressing bone marrow-derived cells enhanced tumor growth in vivo (Kamata et al., 2010) . Taken together, this study suggests that PGE 2 driven by stromal MF-associated mPGES-1, in cooperation with that generated by cancer cell-associated mPGES-1, may act on EP receptors expressed on cancer cells to accelerate their proliferation and/or those on microvascular endothelial cells to promote angiogenesis, eventually leading to tumor propagation.
In conclusion, we have shown that mPGES-1 is involved in multiple steps of carcinogenesis. mPGES-1 in both cancer cells and host cells (MFs) promotes early to late stages of tumor development, likely by altering the balance of pro-and antitumorigenic lipid mediators and thereby modulating several signaling pathways linked to oncogenesis, such as b-catenin, PPARg and NF-kB pathways. Our findings highlight that inhibition of mPGES-1 is an alternative therapeutic target for cancer, including CRC.
Materials and methods

Animals
All animal experiments were approved by the Institutional Animal Care and Use Committees of Showa University. Balb/c and C57BL6 mice were purchased from Saitama Experimental Animals Supply Co. Ltd. (Saitama, Japan). mPGES-1 KO mice were described previously (Kamei et al., 2004 Hara et al., 2010) , and were backcrossed at least 10 generations onto Balb/c mice. For experiments using LLC cells, we used mPGES-1 KO mice on a C57BL/6 background. For the generation of transgenic mice overexpressing mPGES-1 under the b-actin promoter, we inserted the cDNA for mouse mPGES-1 into the CALNL5 vector (Kanegae et al., 1996) , established mPGES-1 transgenic mice as described previously (Ohtsuki et al., 2006) and inbred them with C57BL/6 mice. These mice were housed in microisolator cages in a pathogen-free barrier facility.
Induction of colonic ACF and tumors by AOM treatment mPGES-1 KO mice and their littermate WT mice on the Balb/ c background, or mPGES-1 transgenic mice on the C57BL/6 background and C57BL/6 WT mice (8-25 weeks old), were intraperitoneally injected with AOM at a dose of 10 mg/kg body weight once a week for 6 weeks. Mice were killed 6 or 18 weeks after the last injection of AOM. After laparotomy, the entire colons were dissected and then macroscopically divided into normal-appearing tissues and polyps as normal and tumor tissues, respectively. For microscopic analysis, the dissected colons were filled with 10% neutral-buffered formalin and then opened longitudinally from the anus to the cecum. For analysis of ACF formation, each colon was stained with 0.2% methylene blue in phosphate-buffered saline (PBS). Colon tissues were scored under a light microscope for the number of ACFs or polyps per colon.
Preparation of BM-MFs BM cells were obtained by flushing the cavities of dissected femurs and tibias of mPGES-1 KO or littermate WT mice (6-12 weeks old) with a-minimum essential medium containing 10% fetal calf serum. These BM cells (1 Â 10 5 ) were plated out in medium containing recombinant macrophage-colony-stimulating factor (50 ng/ml; Wako, Osaka, Japan) and cultured for 3 days. Adhering cells were used as BM-MFs.
Intrasplenic transplantation of cancer cells
Cell suspensions containing 10 5 of LLC or 10 4 of colon-26 cells in 100 ml PBS were injected into the spleens of mPGES-1 KO or littermate WT mice (6-12 weeks old). The spleens were weighed after 4 weeks (for the experiment using LLC cells) or after 3 weeks (for the experiment using colon-26 cells). In reconstitution experiments with BM-MFs, BM-MFs (3 Â 10 5 cells in 300 ml of PBS) were intravenously injected into mice 2 days after intrasplenic transplantation of LLC cells.
Immunohistochemistry
Immunohistochemistry of the colon tissue sections was performed as described previously (Kamei et al., 2004) . Briefly, the tissue sections were incubated with Target Retrieval Solution (DAKO Japan, Kyoto, Japan) as required, incubated for 10 min with 3% (v/v) H 2 O 2 , washed three times with Trisbuffered saline (TBS) for 5 min each, incubated with 5% (w/v) skim milk for 30 min, washed three times with TBS-Tween for 5 min each and incubated for 3 h with anti-mPGES-1 antibody (Cayman Chemical, Ann Arbor, MI, USA) in TBS (1:100 dilution) or 45 min with anti-b-catenin antibody (SigmaAldrich, St Louis, MO, USA) in TBS (1:500 dilution). Then, the sections were treated with the Envision staining kit (DAKO Japan), followed by counterstaining with hematoxylin and eosin.
Immunocytostaining LLC cells (10 5 cells) and BM-MFs (10 5 cells) were seeded onto poly-L-lysine-coated plates and cultured for 2 days. Cells were fixed with 3.7% formaldehyde for 30 min in PBS. After three mPGES-1 promotes colon carcinogenesis Y Sasaki et al washes with PBS, the fixed cells were sequentially treated with 0.2% Triton X-100 for 3 min in PBS (for permeabilization), with 3% bovine serum albumin for 1 h in PBS (for blocking), with anti-mPGES-1 (Cayman Chemical) and anti-F4/80 (MF marker) antibodies (AbD Serotec, Oxford, UK) for 2 h in PBS containing 3% bovine serum albumin, and then with Cy3-conjugated donkey anti-rabbit immunoglobulin G (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and fluorescein isothiocyanate-conjugated goat anti-rat immunoglobulin G antibodies (Sigma-Aldrich) for 2 h in PBS containing 3% bovine serum albumin. After six washes with PBS, the fluorescent signals were visualized using a laser scanning confocal microscope LSM510 (Carl Zeiss, Oberkochen, Germany).
Western blotting
Aliquots of samples (20 mg of protein equivalents) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 10% gel under reducing conditions. The separated proteins were electroblotted onto nitrocellulose membranes (Schleicher & Schuell, Hahnenstr, Germany) with a semidry blotter (Bio-Rad Laboratories, Hercules, CA, USA). After blocking with 3% (w/v) skim milk in TBS (pH 7.4) containing 0.05% (v/v) Tween-20 (TBS-Tween), the membranes were probed with the respective antibodies for 2 h (1:5000 dilution for anti-IkB and anti-COX-2 antibodies (Santa Cruz Biotechnology) and 1:2500 dilution for antimPGES-1 (Cayman Chemical) and anti-a-tubulin antibodies (Zymed Laboratories, South San Francisco, CA, USA) in TBS-Tween). They were then incubated with horseradish peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulin G antibodies (1:5000 dilution in TBS-Tween) for 1 h, and visualized with the ECL western blot system (PerkinElmer Life Sciences, Boston, MA, USA), as described previously (Kamei et al., 2003; .
Real-time RT-PCR
Total RNA was extracted from colon mucosa by homogenization in TRIzol reagent. Two micrograms of RNA from each sample were subjected to RT reaction using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). A SYBR Green-based protocol and real-time PCR detection system (Applied Biosystems) were used to detect mRNA levels. The DNA sequences of the primers used are summarized in Supplementary Table 1 . RNA amounts were normalized against the glyceraldehyde 3-phosphate dehydrogenase mRNA level.
Determination of PG levels
For the measurement of PGs, mouse tissues were washed with PBS before homogenization. The supernatants obtained from the tissue homogenates were adjusted to pH 3.0 with 1 N HCl and passed through a Sep-Pak C18 cartridge (Waters, Milford, MA, USA), and the retained PGs were eluted with 3 ml of ethyl acetate/methanol (1:9) solution, as described previously.
A trace amount of [ 3 H]PGE 2 (Cayman Chemical) was added to the samples before passage through the cartridges to calibrate the recovery of the PGs. The sample solvents were evaporated, and then the PGs were dissolved in an aliquot of buffer and assayed with commercial enzyme immunoassay kits for each PG (Cayman Chemical).
Statistical analysis
Data were analyzed by Student's t-test. The results are expressed as means±s.e., with P ¼ 0.05 as the limit of significance.
